Belfast Health and Social Care Trust
caring supporting improving together

FOI/30963

15 April 2024

Treatment of Cancers

[a] Data on numbers of patients from the electronic prescribing system

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	89 +Fulvestrant 13
1.2 Alpelisib (Piqray)	+ Fulvestrant <5
1.3 Fulvestrant (fulvestrant or Faslodex)	43
1.4 Palbociclib (Ibrance)	124 +Fulvestrant 22
1.5 Ribociclib (Kisqali)	51 +Fulvestrant 10

Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Not recorded on RISOH

Number patients treated

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Not recorded on RISOH

Treatment intent	Number patients treated
3.1 Curative	
3.2 Palliative	
3.3 Not known / stated	

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	13
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	22
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	10

[a] Data on numbers of patients from the electronic prescribing system

PROSTATE CANCER

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
5.1 Abiraterone (Zytiga or generic abiraterone)	57
5.2 Apalutamide (Erleada)	37

5.3 Cabazitaxel (Jevtana or generic cabazitaxel)	15
5.4 Darolutamide (Nubeqa)	14
5.5 Enzalutamide (Xtandi)	170

Q6. How many patients were treated with docetaxel specifically for prostate cancer (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
Docetaxel	+Daraoutamide 10 +Prednisolone 27

Q7. How many patients were treated with the following medicine combinations in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Not recorded on RISOH (ADT prescribed by GPs)

Name of medicine	Number patients treated
7.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	
7.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	
7.3 Darolutamide (Nubeqa) + Docetaxel + ADT	
7.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

[a] Data on numbers of patients from the electronic prescribing system

OVARIAN and ENDOMETRIAL CANCERS

Q8. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
8.1 Dostarlimab (Jemperli)	<5
8.2 Niraparib (Zejula)	28
8.3 Rucaparib (Rubraca)	<5

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q9. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
9.1 Olaparib in total	8
9.2 Olaparib monotherapy	8
9.3 Olaparib + bevacizumab in combination	<5
9.4 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	<5

Q10. How many patients were treated for endometrial cancer with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
10.1 Dostarlimab monotherapy	<5
10.2 Dostarlimab + platinum-based chemotherapy, or dostarlimab + carboplatin and paclitaxel	<5
10.3 Pembrolizumab (Keytruda) in total	<5

10.4 Lenvatinib (Lenvima) in total	<5
10.5 Pembrolizumab monotherapy	<5
10.6 Pembrolizumab + Lenvatinib (Lenvima) in combination	<5